Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

completed250%
terminated125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

NCT03310957
unknown

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT06362590
terminatedphase_2

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704
completedphase_1

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643

Clinical Trials (4)

Showing 4 of 4 trials
NCT03310957Phase 1

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
NCT06362590

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

Unknown
NCT04032704Phase 2

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
NCT01969643Phase 1

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4